Patient information: uses, side effects, how to take - Beqalzi
What is the most important information I should know about BEQALZI?
BEQALZI can cause serious side effects, including:
Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure, the need for dialysis treatment, and can be life-threatening. TLS can happen when you first start treatment with BEQALZI, when your dose is increased, or when you restart BEQALZI after stopping treatment. You will receive other medicines before starting and during treatment with BEQALZI to help reduce your risk of TLS. You may also need to receive intravenous (IV) fluids into your vein. Your healthcare provider will do blood tests to check your risk for TLS before you start treatment and during treatment with BEQALZI. It is important to keep your appointments for blood tests.
Tell your healthcare provider right away if you get any symptoms of TLS during treatment with BEQALZI, including:
- nausea
- vomiting
- diarrhea
- muscle cramps, weakness, or twitching
- fatigue
- decreased urination
- swelling in your legs, ankles, or feet
- numbness or tingling, especially around your mouth or in your hands and feet
- confusion or difficulty staying alert
- irregular or fast heart rate
- seizures
Drink plenty of water during treatment with BEQALZI to help reduce your risk of getting TLS.
Drink 6 to 8 glasses (about 1.5 to 2 liters) of water daily:
- starting 1 to 2 days before your first dose,
- on the day of your first dose,
- each time your dose is increased, and
- if you restart BEQALZI after stopping treatment.
- Serious infections. BEQALZI can cause death or serious infections. Your healthcare provider will monitor you for signs and symptoms of infection and treat you as needed. Tell your healthcare provider right away if you develop a fever or any signs of an infection.
See "What are the possible side effects of BEQALZI?" for more information about side effects.
What is BEQALZI?
BEQALZI is a prescription medicine used to treat adults with:
- mantle cell lymphoma (MCL) that has come back or did not respond to previous treatment, and
- who have already received at least 2 treatments for their cancer, including a Bruton's tyrosine kinase (BTK) inhibitor medicine.
It is not known if BEQALZI is safe and effective in children.
Who should not take BEQALZI?
Certain medicines must not be taken when you first start taking BEQALZI and while your dose is being slowly increased because of the increased risk of tumor lysis syndrome (TLS).
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. BEQALZI and other medicines may affect each other causing serious side effects.
- Do not start new medicines during treatment with BEQALZI without first talking with your healthcare provider.
Before taking BEQALZI, tell your healthcare provider about all of your medical conditions, including if you:
- have kidney problems.
- have problems with your body salts or electrolytes, such as potassium, phosphorus, or calcium.
- have a history of high uric acid levels in your blood or gout.
are pregnant or plan to become pregnant. BEQALZI can harm your unborn baby.
Females who are able to become pregnant:
- Your healthcare provider should do a pregnancy test before you start treatment with BEQALZI.
- Use effective birth control (contraception) during treatment and for 1 week after the last dose of BEQALZI.
- Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with BEQALZI.
Males with female partners who are able to become pregnant:
- Use effective birth control (contraception) during treatment and for 1 week after the last dose of BEQALZI.
- are breastfeeding or plan to breastfeed. It is not known if BEQALZI passes into your breast milk. Do not breastfeed during treatment and for 1 week after the last dose of BEQALZI.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking BEQALZI with certain other medicines may affect how BEQALZI works and cause serious side effects. See "Who should not take BEQALZI?"
How should I take BEQALZI?
- Take BEQALZI exactly as your healthcare provider tells you to take it.
- Do not change your dose of BEQALZI or stop taking BEQALZI unless your healthcare provider tells you to. If your healthcare provider stops and restarts BEQALZI, see "How should I restart BEQALZI after my healthcare provider stopped treatment?"
When you first take BEQALZI:
- You may need to take BEQALZI at a hospital or clinic to be monitored for TLS.
- Your healthcare provider will start BEQALZI at a low dose. Your dose will slowly be increased two times each week over a 4-week period until you reach your target dose. Follow your healthcare provider's instructions carefully while increasing to the target dose.
Take BEQALZI 1 time a day with a meal at about the same time each day.
- Swallow BEQALZI tablets whole with a glass of water. Follow the instructions about drinking water described in the "What is the most important information I should know about BEQALZI?" section of this Medication Guide.
- Do not break, chew, or crush the tablets.
- If you miss a dose of BEQALZI and it has been less than 8 hours, take your dose as soon as possible with a meal and resume the normal daily dosing schedule. If you miss a dose of BEQALZI and it has been more than 8 hours, skip the missed dose and take the next dose at your usual time.
- If you vomit after taking BEQALZI, do not take an extra dose. Take the next dose at your usual time the next day.
How should I restart BEQALZI after my healthcare provider stopped treatment?
- If you have side effects, your healthcare provider may tell you to stop taking BEQALZI for a period of time.
- Do not restart BEQALZI on your own. Call your healthcare provider before you start taking BEQALZI again.
Your healthcare provider will tell you:
- when it is safe to restart BEQALZI,
- which dose to take when you restart,
- how to take your restart dose.
- You may restart at the same dose you were taking, or your healthcare provider may have you restart at a lower dose. This depends on how long you have stopped taking BEQALZI.
- Your healthcare provider will restart your treatment using a blister pack or tablets in a bottle. Your healthcare provider may prescribe a new restart pack. Do not use leftover blister packs from your previous treatment without talking to your healthcare provider.
If you restart BEQALZI with a new blister pack:
- Your healthcare provider may tell you to start at the beginning of the blister pack (Day 1) or in the middle of the blister pack (Day 4).
If you are told to start on Day 4 of the blister pack:
- Push the tablets from Days 1, 2, and 3 through the back of the blister pack and throw away the unused tablets in the trash.
- Start taking BEQALZI with the tablets labeled "Day 4" on the blister pack. Take 2 tablets every day for four days.
- Follow your healthcare provider's instructions about what to do next after you finish this blister pack.
If you restart BEQALZI with tablets in a bottle:
- Follow your healthcare provider's instructions about how many tablets to take each day.
What should I avoid while taking BEQALZI?
Avoid drinking grapefruit juice and eating grapefruit products, Seville oranges (often used in marmalades), or star fruit during treatment with BEQALZI. These products may increase the amount of BEQALZI in your blood.
What are the possible side effects of BEQALZI?
BEQALZI can cause serious side effects, including:
- See "What is the most important information I should know about BEQALZI?"
- Decreased white blood cell count (neutropenia). BEQALZI can cause serious or severe decreased white blood cell counts, which can increase the risk of infection. Your healthcare provider will check your blood counts during treatment with BEQALZI.
The most common side effects of BEQALZI include pneumonia and tiredness.
The most common abnormal blood tests with BEQALZI are decreased white blood cell counts.
Your healthcare provider may decrease your dose, temporarily stop, or completely stop treatment with BEQALZI if you get certain side effects.
BEQALZI may cause fertility problems in males and females, which may affect your ability to have a child. Talk to your healthcare provider if you have concerns about fertility.
These are not all the possible side effects of BEQALZI.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store BEQALZI?
- Store BEQALZI at room temperature between 68°F and 77°F (20°C and 25°C).
- For BEQALZI blister packs, store the tablets in the original blister package. Do not transfer the tablets to a different container.
Keep BEQALZI and all medicines out of the reach of children.
General information about the safe and effective use of BEQALZI.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use BEQALZI for a condition for which it was not prescribed. Do not give BEQALZI to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about BEQALZI that is written for health professionals.
What are the ingredients in BEQALZI?
Active ingredient: sonrotoclax
Inactive ingredients: anhydrous dibasic calcium phosphate, colloidal silicon dioxide (20 and 80 mg only), croscarmellose sodium, hydroxypropyl methylcellulose acetate succinate, magnesium stearate, microcrystalline cellulose, talc (20 and 80 mg only). The film coating contains: FD&C Blue No. 1/brilliant blue FCF aluminum lake, FD&C Red No. 40/allura red ac aluminum lake, polyethylene glycol, polyvinyl alcohol, soy lecithin, talc, and titanium dioxide.
Manufactured for:
BeOne Medicines USA, Inc.
Pennington, NJ 08534
BEQALZI is a trademark owned by BeOne Medicines I GmbH or its affiliates.
©BeOne Medicines I GmbH 2026. All rights reserved.
